Prof. Meltem EKENEL

Publication Network

Articles 71

1. Cisplatin-docetaxel induction chemotherapy for patients with nasopharyngeal carcinoma in a non-endemic cohort

ÖZKAYA TORAMAN K., MERAL R., Karadeniz A. N., Kaval G., BAŞARAN M., EKENEL M., et al.

Journal of Chemotherapy , vol.36, no.2, pp.133-142, 2024 (SCI-Expanded)

2. Comparison of second-line treatments in metastatic renal cell carcinoma patients: A single-center experience

Pehlivan M., Paksoy N., Aydin E., BAŞARAN M., EKENEL M.

Medicine , vol.102, no.41, 2023 (SCI-Expanded) Sustainable Development

3. The use of bevacizumab in primary malignant tumors of the central nervous system: A single-center experience

Pehlivan M., EKENEL M.

Medicine , vol.102, no.30, 2023 (SCI-Expanded) Sustainable Development

4. Clinical course and features of soft tissue sarcomas in geriatric patients: a single-center experience

Pehlivan M., İribaş A., Bilgiç B., BAŞARAN M., EKENEL M.

Journal of International Medical Research , vol.51, no.3, 2023 (SCI-Expanded)

5. Multidrug refractory aggressive metastatic TFE3 (+) renal cell carcinoma: A case report.

Paksoy N., Erdem S., Karaca M., Ak N., Pehlivan M., Yirgin İ., et al.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners , vol.28, no.1, pp.215-221, 2022 (SCI-Expanded)

6. The role of the clinical pharmacist in detecting drug interactions and drug-related problems in patients with lung and urogenital system cancer

Sezer S., Akbas M., Dayi B. S., Kara Z. P., Ekenel M., Dogan B. S. U.

INTERNATIONAL JOURNAL OF CLINICAL PHARMACY , vol.43, no.6, pp.1785-1786, 2021 (SCI-Expanded) Sustainable Development

7. A rare case of ruptured liver metastases from a laryngeal cancer

Yirgin I. K., EKENEL M., Simsek D. H., Acunas B.

Radiology Case Reports , vol.16, no.11, pp.3330-3335, 2021 (Scopus) Sustainable Development

8. Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences.

Tural D., Ölmez Ö. F., Sümbül A. T., Artaç M., Özhan N., Akar E., et al.

European urology focus , vol.7, pp.1061-1066, 2021 (SCI-Expanded) Sustainable Development

9. Safety of Fibroblast Activation Protein-Targeted Radionuclide Therapy by a Low-Dose Dosimetric Approach Using Lu-177-FAPI04

Kuyumcu S., Kovan B., Sanli Y., Buyukkaya F., Has Simsek D., Özkan Z. G., et al.

CLINICAL NUCLEAR MEDICINE , vol.46, no.8, pp.641-646, 2021 (SCI-Expanded, Scopus) Sustainable Development

10. Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab

Tural D., Olmez O. F., Sumbul A. T., Ozhan N., ÇAKAR B., Kostek O., et al.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY , vol.26, pp.1506-1513, 2021 (SCI-Expanded) Sustainable Development

11. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Powles T., Csoszi T., ÖZGÜROĞLU M., Matsubara N., Geczi L., Cheng S. Y., et al.

LANCET ONCOLOGY , vol.22, no.7, pp.931-945, 2021 (SCI-Expanded)

12. Can PSMA-based tumor burden predict response to docetaxel treatment in metastatic castration-resistant prostate cancer?

Has Simsek D., Kuyumcu S., Karadogan S., Oflas M., Isik E. G., Ozkan Z. G., et al.

ANNALS OF NUCLEAR MEDICINE , vol.35, no.6, pp.680-690, 2021 (SCI-Expanded, Scopus) Sustainable Development

13. Efficacy of temozolomide in pretreated patients with metastatic sarcoma.

Paksoy N., Dogan I., Ekenel M., Basaran M.

JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.15, 2021 (SCI-Expanded)

14. Efficacy of vincristine, irinotecan, and temozolomide (VIT) combination in adult patients with metastatic Ewing sarcoma.

Dogan I., Iribas A., Ekenel M., Basaran M.

JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.15, 2021 (SCI-Expanded)

15. 177Lu-PSMA Therapy for Metastatic Testicular Mixed Germ Cell Tumor.

Has Simsek D., Civan C., Ekenel M., Kuyumcu S., Sanli Y.

Clinical nuclear medicine , vol.46, no.5, pp.415-418, 2021 (SCI-Expanded, Scopus)

16. Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma.

Paksoy N., Dogan I., Ekenel M., Basaran M.

JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.15, 2021 (SCI-Expanded)

17. Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors.

Ferhatoglu F., Paksoy N., Dogan I., Ak N., Pehlivan M., Ekenel M., et al.

JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.15, 2021 (SCI-Expanded)

18. Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases.

Dogan I., Iribas A., Paksoy N., Ekenel M., Vatansever S., Basaran M.

JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.6, 2021 (SCI-Expanded)

19. Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma.

Tural D., Olmez O. F., Sumbul A. T., Artac M., Ozhan N., Akar E., et al.

JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.6, 2021 (SCI-Expanded)

20. Sunitinib versus pazopanib for patients with metastatic renal cell carcinoma: 2 Turkish hospital experience

EKENEL M., Karabulut S., Cil I., Zirtiloglu A., Aydin E., Tural D.

ACTAS UROLOGICAS ESPANOLAS , vol.44, no.1, pp.27-33, 2020 (SCI-Expanded)

21. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Burtness B., Harrington K. J., Greil R., Soulieres D., Tahara M., de Castro G., et al.

LANCET , vol.394, no.10212, pp.1915-1928, 2019 (SCI-Expanded) Sustainable Development

22. Everolimus-Induced Severe Hypertriglyceridemia and Acute Pancreatitis in a Patient With Tuberous Sclerosis

Sari M., Ekenel M.

AMERICAN JOURNAL OF THERAPEUTICS , vol.26, no.4, 2019 (SCI-Expanded)

23. The expression levels of miRNA-15a and miRNA-16-1 in circulating tumor cells of patients with diffuse large B-cell lymphoma.

Tuncer S. B., Akdeniz D., Celik B., Kilic S., Sukruoglu Ö., Avsar M., et al.

Molecular biology reports , vol.46, no.1, pp.975-980, 2019 (SCI-Expanded)

24. Santral sinir sistemi tümörlerinde immünoonkolojik tedaviler

EKENEL M.

Türkiye Klinikleri , vol.-, pp.23-27, 2018 (Peer-Reviewed Journal)

25. Successful use of docetaxel for emergency treatment of disseminated intravascular coagulation due to hormone-refractory metastatic prostate cancer

KESKİN S., EKENEL M., BAŞARAN M., BAVBEK S.

Journal of Oncological Sciences , vol.3, no.2, pp.81-83, 2017 (Peer-Reviewed Journal) Sustainable Development

26. Neoadjuvant sequential chemoradiotherapy versus radiotherapy alone for treatment of high-risk extremity soft tissue sarcoma: a single-institution experience

Kilic L., Ekenel M., Karabulut S., Agaoglu F., Darendeliler E.

WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY , vol.21, no.1, pp.60-65, 2017 (ESCI)

27. Papillary Renal Cell Carcinoma Arising in a Lymph Node Metastasis of a Testicular Teratoma: A Very Rare Occurrence

Sari S. O., Ozluk Y., Taskin O. C., Polat B., Ozturk I., Ekenel M., et al.

INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY , vol.24, no.5, pp.468-472, 2016 (SCI-Expanded)

28. Beyin tümörlerinde immünolojik tedavi

EKENEL M.

Klinik Tıp Bilimleri Dergisi , vol.4, 2016 (Peer-Reviewed Journal)

29. The Prognostic Factors and Outcome of Adult Medulloblastoma: Where We Stand

Ibis K., Karadeniz A., Meral R., Guveli M., Basaran M., Bavbek S., et al.

INTERNATIONAL SURGERY , vol.101, pp.352-360, 2016 (SCI-Expanded, Scopus)

30. Beyin tümörlerinde hedefe yönelik tedaviler

EKENEL M.

Türkiye Klinikleri , vol.-, pp.14-21, 2016 (Peer-Reviewed Journal)

31. Neoadjuvant sequential chemoradiotherapy versus radiotherapy alone for treatment of high risk extremity soft tissue sarcoma A single institution experience

KILIÇ L., EKENEL M., KARABULUT S., AĞAOĞLU F., DARENDELİLER M. E.

WSPOLCZESNA ONKOLOGIA , 2016 (Scopus)

32. Diagnostic value of serum M30 and M65 in patients with nasopharyngeal carcinoma

Sen F., Yildiz I., Odabas H., Tambas M., Kilic L., Karadeniz A., et al.

TUMOR BIOLOGY , vol.36, pp.1039-1044, 2015 (SCI-Expanded, Scopus) Sustainable Development

33. Sunitinib ile tedavi edilen metastatik böbrek hücreli karsinom hastalarının klinik olarak değerlendirilmesi: Tek merkez deneyimi

KARABULUT S., EKENEL M., IRIBAS A., DARENDELILER E., BAŞARAN M., BAVBEK S. E.

TÜRK ONKOLOJİ DERGİSİ , vol.30, pp.51-60, 2015 (Scopus)

34. Clinical evaluation of sunitinib in patients with metastatic renal cell carcinoma: Single center experience

Karabulut S., Ekenel M., Iribas A., Darendeliler E., Basaran M., Bevbek S.

TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY , vol.30, no.2, pp.51-60, 2015 (ESCI)

35. Gliom tedavisinde kemoterapi

EKENEL M., TEOMETE M., ÖZDUMAN K.

Kanser Gündemi Dergisi , vol.2, pp.59-61, 2014 (Peer-Reviewed Journal)

36. Sunitinib for Patients with Metastatic Non-clear Cell Renal Cell Carcinoma: A Multicenter Retrospective Turkish Oncology Group Trial

YILDIZ I., Ekenel M., AKMAN T., KOCAR M., Uysal M., Kanitez M., et al.

ANTICANCER RESEARCH , vol.34, no.8, pp.4329-4334, 2014 (SCI-Expanded) Sustainable Development

37. Survival and Prognostic Factors in Adult Patients with Recurrent or Refractory Ewing Sarcoma Family Tumours: A 13-Years Retrospective Study in Turkey

Yildiz I., Sen F., Ekenel M., Darendeliler E., Bavbek S., Agaoglu F., et al.

IN VIVO , vol.28, no.3, pp.403-409, 2014 (SCI-Expanded)

38. Associations between clinicopathological prognostic factors and pAkt, pMAPK and topoisomerase II expression in breast cancer

Iyikesici M. S., BAŞARAN G., DANE F., Ekenel M., YUMUK P. F., ÇABUK D., et al.

INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE , vol.7, no.5, pp.1459-1464, 2014 (SCI-Expanded) Sustainable Development

39. Prognostic factors associated with the response to sunitinib in patients with metastatic renal cell carcinoma

YILDIZ I., Sen F., Kilic L., Ekenel M., Ordu C., Kilicaslan I., et al.

CURRENT ONCOLOGY , vol.20, no.6, 2013 (SCI-Expanded)

40. Comparison of two different adjuvant treatment modalities for pN3 gastric cancer patients after D2 lymph node dissection: can we avoid radiotherapy in a subgroup of patients?

Kilic L., ORDU C., Ekenel M., Yildiz I., Keskin S., Sen F., et al.

MEDICAL ONCOLOGY , vol.30, no.3, 2013 (SCI-Expanded) Sustainable Development

41. Serum M65 as a Biomarker for Metastatic Renal Cell Carcinoma

Yildiz I., Sen F., Kilic L., Keskin S., Duranyildiz D., Bilgin E., et al.

CLINICAL GENITOURINARY CANCER , vol.11, no.3, pp.290-296, 2013 (SCI-Expanded) Sustainable Development

42. Impaired coronary flow reserve in metastatic cancer patients treated with sunitinib

Sen F., Yildiz I., Başaran M., Ekenel M., Oz F., Kilic L., et al.

JOURNAL OF BUON , vol.18, no.3, pp.775-781, 2013 (SCI-Expanded) Sustainable Development

43. Biweekly triplet chemotherapy with gemcitabine, cisplatin and vinorelbine for advanced chemotherapy naïve non-small cell lung cancer.

Keskin S., Tas F., Ekenel M., Kilic L., Sen F., Yildiz I., et al.

Tumori , vol.99, no.4, pp.463-8, 2013 (SCI-Expanded, Scopus) Sustainable Development

44. What is the Role of Enlarged Lymph Node Resection Alone in Patients With Nonseminomatous Germ Cell Tumor Who Had Stage II or III Disease?

Ekenel M., Keskin S., Sanli O., Bavbek S., Tunc M., Ander H., et al.

CLINICAL GENITOURINARY CANCER , vol.10, no.3, pp.185-189, 2012 (SCI-Expanded)

45. Predictive Value of Marker Half-life in Relapsed and Nonrelapsed Nonseminomatous Germ Cell Testicular Tumor Patients Undergoing Chemotherapy

Keskin S., Ekenel M., Basaran M., Bavbek S.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS , vol.35, no.4, pp.369-372, 2012 (SCI-Expanded)

46. Clinicopathological characteristics and treatment outcomes of adult patients with paratesticular rhabdomyosarcoma (PRMS): A 10-year single-centre experience

Keskin S., Ekenel M., Basaran M., Kilicaslan I., Tunc M., Bavbek S.

CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL , vol.6, no.1, pp.42-45, 2012 (SCI-Expanded)

47. Response Rates and Adverse Effects of Continuous Once-daily Sunitinib in Patients with Advanced Renal Cell Carcinoma: A Single-center Study in Turkey

Yildiz I., Sen F., Basaran M., Ekenel M., Agaoglu F., Darendeliler E., et al.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY , vol.41, no.12, pp.1380-1387, 2011 (SCI-Expanded)

48. The First Case of Primary Testicular Germ Cell Tumor Containing Nephroblastoma as the Only One Non-germ Cell Component

Keskin S., Ekenel M., Basaran M., Aksu C., Kilicaslan I., Tunc M., et al.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY , vol.41, no.8, pp.1037-1040, 2011 (SCI-Expanded)

49. Induction chemotherapy with docetaxel and cisplatin is highly effective for locally advanced nasopharyngeal carcinoma

Ekenel M., Keskin S., Basaran M., Ozdemir C., Meral R., Altun M., et al.

ORAL ONCOLOGY , vol.47, no.7, pp.660-664, 2011 (SCI-Expanded)

50. Comparison of two different adjuvant treatment approaches for patients with locally advanced gastric cancer

Ekenel M., OZER L., ORDU C., SAGLAM E. K., KIZIR A., ORAL E. N., et al.

JOURNAL OF CLINICAL ONCOLOGY , vol.29, no.15, 2011 (SCI-Expanded) Sustainable Development

51. Does the Timing of Radiotherapy Impact Survival of Glioblastoma Multiforme Patients?

Tezcanli E. K., Ucuncu A., Sarihan S., AKSU A., EROĞLU C., ALCO G., et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS , vol.81, no.2, 2011 (SCI-Expanded)

52. Kadın genital sistem kanserlerinin moleküler biyolojisi ve karsinogenezi

EKENEL M., SAİP P.

Türkiye Klinikleri , vol.4, pp.1-6, 2011 (Peer-Reviewed Journal) Sustainable Development

53. Surveillance Results of Patients with Stage I Nonseminomatous Germ Cell Testicular Cancer

Keskin S., Ekenel M., Basaran M., Bavbek S.

ONKOLOGIE , vol.34, no.4, pp.173-176, 2011 (SCI-Expanded) Sustainable Development

54. Clinical outcomes in patients with locally advanced nasopharyngeal cancer treated with neoadjuvant docetaxel and cisplatin followed by radiation treatment and concomitant cisplatin

Ekenel M., Keskin S., Bassaran M., Bavbek S. E., Ozdemir C., Meral R., et al.

JOURNAL OF CLINICAL ONCOLOGY , vol.28, no.15, 2010 (SCI-Expanded) Sustainable Development

55. Surveillance results of patients with stage I nonseminomatous testis cancer

Keskin S., Ekenel M., Başaran M., Esen T., Ozcan F., Tunc M., et al.

JOURNAL OF CLINICAL ONCOLOGY , vol.28, no.15, 2010 (SCI-Expanded) Sustainable Development

56. Primary central nervous system lymphoma: The role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy

Ekenel M., IWAMOTO F. M., BEN-PORAT L. S., PANAGEAS K. S., YAHALOM J., DEANGELIS L. M., et al.

CANCER , vol.113, no.5, pp.1025-1031, 2008 (SCI-Expanded)

57. Capecitabine therapy of central nervous system metastases from breast cancer

Ekenel M., HORMIGO A. M., PEAK S., DEANGELIS L. M., ABREY L. E.

JOURNAL OF NEURO-ONCOLOGY , vol.85, no.2, pp.223-227, 2007 (SCI-Expanded) Sustainable Development

58. What is the role of whole brain radiation therapy (WBRT) and high-dose cytarabine (Ara-C) as consolidation treatment after initial chemotherapy for primary CNS lymphoma (PCNSL)?

Ekenel M., IWAMOTO F. M., BEN PORAT L. S., PANAGEAS K. S., YAHALOM J., DEANGELIS L. M., et al.

JOURNAL OF CLINICAL ONCOLOGY , vol.25, no.18, 2007 (SCI-Expanded)

59. Treatment of primary central nervous system lymphoma

Ekenel M., DEANGELIS L. M.

CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS , vol.7, no.3, pp.191-199, 2007 (SCI-Expanded)

60. Vascular endothelial growth factor, hypoxia-inducible factor 1 alpha and CD34 expressions in early-stage gastric tumors: Relationship with pathological factors and prognostic impact on survival

CABUK D., BASARAN G., CELIKEL C., DANE F., YUMUK P. F., IYIKESICI M. S., et al.

ONCOLOGY , vol.72, pp.111-117, 2007 (SCI-Expanded) Sustainable Development

61. HPV DNA frequency and subset analysis in human breast cancer patients' normal and tumoral tissue samples

GUMUS M. D., YUMUK P. F., SALEPCI T., ALIUSTAOGLU M., DANE F., Ekenel M., et al.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH , vol.25, no.4, pp.515-521, 2006 (SCI-Expanded) Sustainable Development

62. Does the incidence of anal canal cancers differ in Moslem societies?

Yumuk P., Abacioglu U., Demir G., Cabuk D., Dane F., Gumus M., et al.

INTERNATIONAL JOURNAL OF COLORECTAL DISEASE , vol.20, no.1, pp.76, 2005 (SCI-Expanded) Sustainable Development

63. D-dimer - Can it be a marker for malignant gastric lesions?

ALIUSTAOGLU M., YUMUK P., GUMUS M. D., Ekenel M., BOLUKBAS F., BOLUKBAS C., et al.

ACTA ONCOLOGICA , vol.43, no.8, pp.770-771, 2004 (SCI-Expanded)

64. The absence of early diarrhea with atropine premedication during irinotecan therapy in metastatic colorectal patients

YUMUK P., AYDIN S., DANE F., GUMUS M. D., Ekenel M., ALIUSTAOGLU M., et al.

INTERNATIONAL JOURNAL OF COLORECTAL DISEASE , vol.19, no.6, pp.609-610, 2004 (SCI-Expanded) Sustainable Development

65. Attitude toward genetic testing for cancer risk in Istanbul

YUMUK P., GUMUS M. D., Ekenel M., BASARAN G., ALIUSTAOGLU M., TOPAL A., et al.

GENETIC TESTING , vol.8, no.2, pp.169-173, 2004 (SCI-Expanded) Sustainable Development

66. Clinical features and adjuvant treatment outcomes of colon cancer (cc) in two outpatient populations of Knoxville, Tennessee and Istanbul, Turkey

DANE F., Turhal N. S., Lyikesici S., Gumus M., YUMUK P. F., Basaran G., et al.

ANNALS OF ONCOLOGY , vol.15, pp.95, 2004 (SCI-Expanded) Sustainable Development

67. Treatment outcomes in non-small cell lung cancer (NSCLC) patients: Comparison between Marmara University, Istanbul, Turkey and Knoxville, Tennessee

Iyikesici S., Turhal N. S., YUMUK P. F., DANE F., Gumus M., Basaran G., et al.

ANNALS OF ONCOLOGY , vol.15, pp.195-196, 2004 (SCI-Expanded) Sustainable Development

68. Clinical outcome of breast cancer (BC) patients (pts) with pT1N0M0 disease

Basaran G. A., Ekenel M., Demirkalem P., Cakir T., Gulluoglu B., GUMUS M., et al.

ANNALS OF ONCOLOGY , vol.15, pp.68, 2004 (SCI-Expanded) Sustainable Development

69. Effects of selective COX-2 inhibitors on the gastric permeability of sucrose: a controlled study with placebo and ibuprofen

Ekenel M., AVSAR E., IMERYUZ N., YUKSEL M., HAKLAR G., KOCAKAYA O., et al.

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY , vol.15, no.4, pp.403-406, 2003 (SCI-Expanded)

70. Scleredema of Buschke associated with Waldenstrom's macroglobulinaemia

RATIP S., AKIN H. S., ÖZDEMİRLİ M., YUCELTEN D., KUS S., Ekenel M., et al.

BRITISH JOURNAL OF DERMATOLOGY , vol.143, no.2, pp.450-452, 2000 (SCI-Expanded)

71. Remitting seronegative symmetrical synovitis with pitting oedema associated with chronic lymphocytic leukaemia

Ekenel M., YAVUZ S., KARTI S., DIRESKENELI H., AKOGLU T.

CLINICAL RHEUMATOLOGY , vol.19, no.3, pp.247-248, 2000 (SCI-Expanded)

Papers Presented at Peer-Reviewed Scientific Conferences 99

1. The efficacy of prognostic factors derived from Ga68-PSMA PET-CT images in predicting treatment response and survival in patients with metastatic castration-resistant prostate cancer treated with Lu-177PSMA

Oflas M., Has Şimşek D., Şanlı Y., Kuyumcu S., Işık E. G., Karadoğan S., et al.

EANM’23, Vienna, Austria, 9 - 13 September 2023, (Full Text) Sustainable Development

2. LU177-PSMA TEDAVİSİ VERİLEN PROSTAT KANSERLİ HASTALARDA GA-68 PET/BT İLE TEDAVİ YANITI VE PROGNOSTİK DEĞERLENDİRME

Oflas M., Has Şimşek D., Şanlı Y., Kuyumcu S., Işık E. G., Karadoğan S., et al.

35. Ulusal Nükleer Tıp Kongresi, Antalya, Turkey, 26 - 30 April 2023, (Summary Text) Sustainable Development

3. The Role of the Clinical Pharmacist in Detecting Drug Interactions and Drug-Related Problems in Patients with Lung and Urogenital System Cancer

SEZER S., AKBAŞ M., DAYI B. S., PALA KARA Z., EKENEL M., UYDEŞ DOĞAN B. S.

49th ESCP Symposium, Netherlands, 19 October 2021, (Summary Text)

4. Induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT) in nasopharyngeal carcinoma(NPC) patients treated between 2004 and 2016: Patient and treatment characteristics and long term outcome.

Altun M., Kaval G., Ibis K., Ozkaya K., Meral R., Karadeniz A. N., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2019, vol.37, (Summary Text)

5. Nazofarenks kanserinde indüksiyon kemoterapi ve eşzamanlı kemoradyoterapi. , 17-21 Nisan 2019, Antalya.

ALTUN M., KAVAL G., İBİŞ K., ÖZKAYA TORAMAN K., MERAL R., KARADENİZ A. N., et al.

23. Ulusal Kanser Kongresi, Antalya, Turkey, 17 - 21 April 2019, (Full Text)

6. Nazofarenks kanserinde yaş gruplarına göre hastalık kontrolü ve sağkalım. 17-21 Nisan 2019, Antalya.

İBİŞ K., KAVAL G., MERAL R., KARADENİZ A. N., ÖZKAYA TORAMAN K., KEBUDİ R., et al.

23. Ulusal Kanser Kongresi, Turkey, 17 - 21 April 2019, (Full Text)

7. Nazofarinks Kanserinde Yaş Gruplarına Göre Hastalık Kontrolü Ve Sağkalım

Ibiş K., Kaval G., Meral R., Karadeniz A., Özkaya K., Kebudi R., et al.

23. Ulusa Kanser Kongresi, 17.21.Nisan 2019 Antalya, Antalya, Turkey, 17 - 21 April 2019, pp.165-166, (Full Text) Sustainable Development

8. Nazofarenks Kanserinde İndüksiyon Kemoterapi ve Eşzamanlı Kemoradyoterapi

Altun M., Kaval G., İbiş K., Özkaya K., Meral R., Karadeniz A., et al.

23. Ulusa Kanser Kongresi, 17.21.Nisan 2019 Antalya, Antalya, Turkey, 17 - 21 April 2019, pp.244-245, (Summary Text) Sustainable Development

9. Yinelenen Nazofarenks karsinomunda Hipofraksiyone Radyasyon tedavisinin sağkalıma etkisi

MERAL R., OKUTAN M., EKENEL M., KARADENİZ A. N., ALTUN M.

13. Ulusal Radyasyon Onkolojisi Kongresi, İstanbul, Turkey, 27 April - 01 May 2018, vol.33, pp.42, (Summary Text)

10. Sunitinib versus pazopanib for patients with metastatic renal cell carcinoma: Two Turkish hospital experience, a retrospective comparative case series study

Ekenel M., Aydın E., CIL I., ZIRTILOGLU A., TURAL D., KARABULUT S.

42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid, Spain, 8 - 12 September 2017, vol.28, (Summary Text)

11. Yineleyen Nazofarinks Karsinomunda Hipofraksiyone Radyasyon Tedavisinin Sağkalıma Etkisi

Meral R., Okutan M., Ekenel M., Karadeniz A. N., Altun M.

13. Ulusal Radyasyon Onkolojisi Kongresi, 27 nisan-01.mayıs 2018, KKTC, Gazimagusa, Cyprus (Kktc), 27 April - 01 May 2018, pp.73, (Summary Text)

12. Erişkin medulloblastomada tedavi deneyim

İBİŞ K., KARADENİZ A. N., MERAL R., güveli m., BAŞARAN M., BAVBEK S., et al.

11. Ulusal Radyasyon Onkolojisi Kongresi, Turkey, 23 - 26 April 2014, (Summary Text)

13. Metastatik hormona dirençli prostat kanserinde abirateron deneyimiz

KARABULUT S., EKENEL M., ÇİFTÇİ R., ÇELEBİ K., İRİBAŞ A., DARENDELİLER M. E., et al.

Avrasya Üronkoloji Bahar Kongresi, Bursa, Turkey, 28 April - 01 May 2016 Sustainable Development

14. Olgu bildirimi: Nüks düşük gradlı glial tümörde bevasizumab sonrası wallerian dejenerasyon

KILIÇ L., EKENEL M., YILDIZ I., ŞEN F., ÇİFTÇİ R., BAŞARAN M., et al.

6. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 23 - 27 March 2016, pp.346, (Full Text)

15. Yüksek gradli glial tümörlerde yeni yaklaşımlar

EKENEL M.

6. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 23 - 27 March 2016, pp.72-73, (Full Text)

16. Metastatik böbrek hücreli tümörlerde sunitinib sonrası everolimus etkinliği

EKENEL M., KARABULUT S., IRIBAS A., DARENDELİLER E., BAVBEK S., BAŞARAN M.

21. Ulusal Kanser Kongresi, Antalya, Turkey, 22 - 26 April 2015, pp.553, (Full Text)

17. Metastatik kastrasyona dirençli prostat kanserinde abireteron deneyimimiz

EKENEL M., ÇİFTÇİ R., KARABULUT S., ÇELEBİ K., IRIBAS A., DARENDELİLER E., et al.

21. Ulusal Kanser Kongresi, Antalya, Turkey, 22 - 26 April 2015, pp.552, (Full Text) Sustainable Development

18. Opere yumuşak doku sarkomlu hastalarda postoperatif radyoterapi sonuçları

IRIBAS A., ÖZKURT S., AĞAOĞLU F., BAŞARAN M., ÖZGER H., ERALP L., et al.

21. Ulusal Kanser Kongresi, Antalya, Turkey, 22 - 26 April 2015, pp.517, (Full Text)

19. Yüksek vücut kitle indeksi (VKİ)hedefe yönelik tedavi alan metastatik renal hücreli karsinom (BHK) hastalarında daha iyi sağkalımı öngörüyor mu?

KARABULUT S., EKENEL M., YILDIZ I., IRIBAS A., DARENDELİLER E., BAŞARAN M., et al.

21. Ulusal Kanser Kongresi, Antalya, Turkey, 22 - 26 April 2015, pp.552, (Full Text)

20. Trombozu olan metastatik böbrek hücreli tümörlerde sunitinib tedavisinin sonuçları

EKENEL M., KARABULUT S., IRIBAS A., DARENDELİLER E., BAVBEK S., BAŞARAN M.

21. Ulusal Kanser Kongresi, Antalya, Turkey, 22 - 26 April 2015, pp.552, (Full Text)

21. Sunitinib ile tedavi edilen metastatik renal hücreli karsinom (MRHK)hasta sonuçları, tek merkez deneyimi

EKENEL M., KARABULUT S., YILDIZ İ., IRIBAS A., DARENDELİLER E., BAŞARAN M., et al.

21. Ulusal Kanser Kongresi, Antalya, Turkey, 22 - 26 April 2015, pp.256, (Full Text)

22. Clinical evaluation of sunitinib in patients with advanced renal cell carcinoma: The Turkish experience

EKENEL M.

SUNNY-Turkish Council of Higher Education Joint Conference, Albany, United States Of America, 15 - 17 April 2015, (Full Text)

23. Distribution and frequency of BRCA gene mutations in Turkish population including Balkan Turks

AKDENIZ D., Tuncer B. S., kılıç S., şükrüoğlu O., Kilic L., ALTUNDAĞ K., et al.

AACR Special Conference on Cancer Susceptibility and Cancer Susceptibility Syndromes, California, United States Of America, 29 January - 01 February 2014, vol.74, (Summary Text)

24. Metastatik renal hücreli karsinomda antianjiojenik hedef tedavi yanıtının değerlendirilmesi

ENGİN G., ŞAHİN D., EKENEL M.

35. Ulusal Radyoloji Kongresi, Antalya, Turkey, 11 - 16 November 2014, (Full Text)

25. Sunitinib in patients with metastatic non-clear renal cell carcinoma: A multicentric retpospective Turkish Oncology Group (TOG) trial.

Yildiz I., Ekenel M., Altman T., KOCAR M., Uysal M., Kanitez M., et al.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32, (Summary Text)

26. Investigation of mir-15a/mir-16-1 expression levels in B-cell non-Hodgkin lymphomas.

Yazici H., kılıç S., avşar M., Sukruoglu O., AKDENIZ D., Ekenel M., et al.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32, (Summary Text)

27. Erişkin Medulloblastomada Tedavi Deneyimi

İbiş K., Karadeniz A., Meral R., Güveli M., Başaran M., Bavbek S., et al.

11. Ulusal Radyasyon Onkolojisi Kongresi, 23-27 Nisan 2014 ANTALYA, Antalya, Turkey, 23 - 27 April 2014, pp.185, (Summary Text)

28. Sisplatine bağlı tuz kaybettiren Nefropati: Olgu sunumu

Gürdal N., Tambaş M., Çiftçi R., Güveli M. E., Özkaya K., Ekenel M., et al.

11. Ulusal Radyasyon Onkolojisi Kongresi, 23-27 Nisan 2014 ANTALYA, Antalya, Turkey, 23 - 27 April 2014, pp.254, (Summary Text)

29. Kalıtsal meme kanser hastalarında saptanan BRCA1 2 gen mutasyonlarının bölgesel ve etnik dağılımı ile klinik özellikleri

AKDENİZ ÖDEMİŞ D., TUNCER B., KILIÇ S., ŞÜKRÜOĞLU Ö., ALTUNDAĞ K., KILIÇ L., et al.

5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014 Sustainable Development

30. Nüks ya da primer refrakter ewing sarkomlu hastalarda sağkalım ve genel sağkalımla ilişkili prognostik faktörler: 13 yıllık tek merkez deneyimi

YILDIZ İ., ŞEN F., EKENEL M., DARENDELİLER E., AĞAOĞLU F., BAVBEK S., et al.

5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.321, (Full Text)

31. ANTİ-VEGF TKİ VERİLEN BEYİN METASTAZLI RENAL HÜCRELİ KANSER OLGULARINDA KLİNİK SONUÇLAR VE PROGNOSTİK FAKTÖRLER: ÇOK MERKEZLİ TOG ÇALIŞMASI İLK SONUÇLARI

YILDIZ I., EKENEL M., AKMAN T., BAYOGLU I. V., TURAL D., YAZICI O., et al.

5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.549, (Full Text) Sustainable Development

32. Metastatik berrak hücreli dışı kanserde sunitinib tedavisinin etkinliği ve tosisitesi: Çok merkezli retrospektif TOG çalışması

YILDIZ İ., EKENEL M., AKMAN T., KOCAR M., UYSAL M., KANITEZ M., et al.

5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.326-327, (Full Text) Sustainable Development

33. Küçük hücreli dışı akciğer kanserli hastalarda anjijenik markırların prognostik ve prediktif rolü

KESKİN S., KILIC L., YILDIZ I., ÇİFTÇİ R., KARABULUT S., ŞEN F., et al.

5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 March 2014 - 23 April 2013, pp.333, (Full Text) Sustainable Development

34. Platin dirençli nüks eden baş boyun tümörlerinde setuximabın rolü, olgu değerlendirmesi

Karabulut S., Ekenel M., Tambaş M., Taştekin D., Altun M., Meral R., et al.

5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.363, (Full Text)

35. Kalıtsal meme kanseri hastalarında saptanan BRCA1/2 gen mutasyonlarının bölgesel ve etnik dağılımları ile klinik özellikleri

AKDENIZ D., TUNCER B. S., KILIC S., SUKRUOGLU Ö., ALTUNDAG K., KILIÇ L., et al.

5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.285, (Full Text) Sustainable Development

36. KALITSAL MEME KANSER HASTALARINDA SAPTANAN BRCA1/2 GEN MUTASYONLARININ BÖLGESEL VE ETNİK DAĞILIMI İLE KLİNİK ÖZELLİKLERİ

AKDENİZ ÖDEMİŞ D., TUNÇER Ş. B., kılıç S., şükrüoğlu Ö., altundağ k., kılıç l., et al.

5. türk tıbbi onkoloji kongresi, Antalya, Turkey, 19 - 23 March 2014, (Full Text) Sustainable Development

37. Glioblastoma multiforme tedavisinde hangi aşamadayız? Moleküler belirteçleri tedavide nasıl kullanmalıyız?

EKENEL M.

5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 13 - 23 March 2014, pp.117-118, (Full Text)

38. Effect of increased body mass index on time to tumor progression in metastatic unresectable colorectal cancer patients treated with bevacizumab-based therapy

Yildiz I., Sen F., Kilic L., Keskin S., Ciftci R., Ekenel M., et al.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31, (Summary Text) Sustainable Development

39. B-Hücreli Hodgkin Dışı Lenfomada miR-15a / miR-16-1 Genlerinin İfade Düzeylerinin Araştırılması

TUNÇER Ş. B., kılıç l., EKENEL M., YAZICI H.

20.Ulusal Kanser Kongresi, İstanbul, Turkey, 20 - 23 April 2013, pp.709, (Full Text)

40. Türk Toplumundaki Meme Kanserli Hastalarda BRCA Mutasyon Dağılımlarının Klinik Faktörlerle İlişkisi

kılıç l., ŞEN F., Yıldız i., keskin s., KARANLIK H., EKENEL M., et al.

20.Ulusal Kanser Kongresi, Antalya, Turkey, 20 - 23 April 2013, (Full Text) Sustainable Development

41. 2008-2012 yılları arasında kanser genetiği polikliniğine başvuran yüksek riskli meme/over kanser sendromlu vakaların dağılımı

AKDENIZ D., ALTUNDAG K., EKENEL M., SUKRUOGLU Ö., KILIC S., KILIÇ L., et al.

20. Ulusal Kanser Kongresi, Antalya, Turkey, 19 - 23 April 2013, pp.381, (Full Text) Sustainable Development

42. B-Hücreli Hodgkin dışı lenfomada MİR-15A/MİR-16-1 genlerinin ifade düzeylerinin araştırılması

TUNCER B. S., KILIC L., EKENEL M., DALAY N., YAZICI H.

20. Ulusal Kanser Kongresi, Antalya, Turkey, 19 - 23 April 2013, pp.381, (Full Text)

43. Mesane kanseri tanılı hastalarda organ koruyucu tedavi sonuçlarımız

IRIBAS A., AĞAOĞLU F., ÖZKURT S., KILIC L., EKENEL M., BAŞARAN M., et al.

20. Ulusal Kanser Kongresi, Antalya, Turkey, 19 - 23 April 2013, pp.173, (Full Text) Sustainable Development

44. Rezektabl desmoid tümörlerde pozitif cerrahi sınırın ve postoperatif radyoterapinin klinik önemi

KARABULUT S., KESKİN S., EKENEL M., ÇİFTÇİ R., BAŞARAN M., AĞAOĞLU F., et al.

20. Ulusal Kanser Kongresi, Antalya, Turkey, 19 - 23 April 2013, pp.274, (Full Text)

45. Modified DCF (mDCF) regimen seems to be as effective as original DCF in advanced gastric cancer (AGC)

Keskin S., Sen F., AYDOGAN F., Ekenel M., Kilic L., SAGLAM S., et al.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30, (Summary Text) Sustainable Development

46. Meme kanserli hastalarda plazma D-Dimer düzeylerinin tümör yükü ve metastazı ile ilişkisi

KILIC L., ŞEN F., YILDIZ İ., KESKİN S., EKENEL M., SERİLMEZ M., et al.

4. Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2012, pp.250, (Full Text) Sustainable Development

47. Olgu bildirimi: 17 yıl sonra nüks eden bir testis tümörü olgusu, malign germ hücreli tümörlerde geç nükslerin önemi

KILIC L., SEN F., YILDIZ İ., KESKİN S., EKENEL M., BAŞARAN M.

4. Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2012, pp.202, (Full Text)

48. Metastatik böbrek hücreli kanserde sunitinib tedavisi altındaki hastalarda prognostik faktörler

YILDIZ İ., ŞEN F., BAŞARAN M., EKENEL M., KILIC L., BAVBEK S.

4. Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2012, pp.123, (Full Text) Sustainable Development

49. Türk toplumunda meme kanserli hastalarda BRCA mutasyonlarının dağılımı ve sağkalımla ilişkisi

KILIC L., KILIC S., SUKRUOGLU Ö., TUNCER B. S., EKENEL M., YAZICI H., et al.

4. Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2012, pp.215, (Full Text) Sustainable Development

50. Türk toplumunda metastatik böbrek kanserinde kesintisiz, günde tek doz olarak verilen sunitinib tedavisinin toksisitesi

BAŞARAN M., YILDIZ I., ŞEN F., EKENEL M., BAVBEK S.

4. Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2012, pp.110, (Full Text) Sustainable Development

51. Olgu bildirimi: Tekrarlayan düşük gradlı glial tümörde bevasizumab ve irinotekanla tam yanıt

KILIC L., EKENEL M., YILDIZ İ., ŞEN F., KESKİN S., AYDOGAN F., et al.

4. Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2012, pp.161, (Full Text)

52. Sunitinib ile tedavi edilen metastatik kanserli hastalarda koroner akım rezervinin değerlendirilmesi

SEN F., YILDIZ I., BAŞARAN M., EKENEL M., KILIÇ L., ÖZ F., et al.

4. Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2012, pp.294, (Full Text) Sustainable Development

53. Olgu bildirimi: Desmoplastik küçük yuvarlak hücreli tümör, uzun süreli sağkalım mümkün mü?

KILIC L., EKENEL M., ŞEN F., YILDIZ İ., KESKİN S., AYDOGAN F., et al.

4. Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2012, pp.180, (Full Text)

54. Akciğer kanserinde koagülasyon testlerinin prognostik önemi

KILIC L., YILDIZ İ., ŞEN F., EKENEL M., KESKİN S., BİLGİN DOĞRU E., et al.

4. Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2012, pp.150-151, (Full Text) Sustainable Development

55. Clinicopathological characteristics and survival rate in patients with BRCA1/2 linked ovarian cancer in Turkey

KESKİN S., EKENEL M., KILIC S., SUKRUOGLU O., AYDINER A., ERALP Y., et al.

2nd Mediterranean Multidisciplinaty Oncology Forum, İstanbul, Turkey, 17 - 19 November 2011, (Full Text) Sustainable Development

56. Predictive significance of marker half life during chemotherapy in relapsed and non relapsed patients with non seminomatous germ cell testicular tumors

KESKİN S., EKENEL M., KARABULUT S., BAŞARAN M., BAVBEK S.

2nd Mediterranean Multidisciplinary Oncology Forum, İstanbul, Turkey, 17 - 19 November 2011, (Full Text)

57. Noncutaneous melanoma have distinct features from each other and cutaneous melanoma

KESKİN S., EKENEL M., YILDIZ İ., KILIÇ L., KARABULUT S., ŞEN F., et al.

2nd Mediterranean Multidisciplinary Oncology Forum, İstanbul, Turkey, 17 - 19 November 2011, (Full Text)

58. Meme kanseri hastalarında yeniden evrelendirme amaçlı PET-BT'nin rolü

KUYUMCU S., KARAGÖZ F., ŞANLI Y., EKENEL M., YILDIZ İ., KARABULUT S., et al.

19. Ulusal Kanser Kongresi, Antalya, Turkey, 20 - 24 April 2011, pp.423, (Full Text) Sustainable Development

59. Glioblastoma hastalarında Ki-67 proliferasyon indeksinin prognostik önemi: TOG-SSS tümörleri grubu çalışması

TEZCANLI E., ÜÇÜNCÜ A., KAMER S., SARIHAN S., EKENEL M., OKKAN S., et al.

19. Ulusal Kanser Kongresi, Antalya, Turkey, 20 - 24 April 2011, pp.46, (Full Text)

60. Glioblastoma multiforme hastalarında cerrahi-radyoterapi arası sürenin önemi var mı? TOG-SSS Tümörleri grubu çalışması

TEZCANLI E., ÜÇÜNCÜ A., SARIHAN S., AKSU A., EROĞLU C., ALÇO G., et al.

19. Ulusal Kanser Kongresi, Antalya, Turkey, 20 - 24 April 2011, pp.45, (Full Text)

61. Mide kanserinde leptomeningeal metastaz-olgu bildirimi

KILIÇ L., EKENEL M., YILDIZ I., SEN F., KESKİN S., AYKAN F. N.

19. Ulusal Kanser Kongresi, Antalya, Turkey, 20 - 24 April 2011, pp.251, (Full Text) Sustainable Development

62. K-RAS mutasyonları ve bevasizumab etkinliği arasında ilişki var mıdır?

KILIÇ L., EKENEL M., YALNIZ Z., ŞEN F., YILDIZ İ., KARANLIK H., et al.

19. Ulusal Kanser Kongresi, Antalya, Turkey, 20 - 24 April 2011, pp.234, (Full Text)

63. OUTCOME OF BRAIN METASTASES FROM COLORECTAL CANCER; A SINGLE INSTITUTE EXPERIENCE

Ekenel M., Kilic L., AYKAN F. N.

35th European-Society-for-Medical-Oncology (ESMO) Congress, Milan, Italy, 8 - 12 October 2010, vol.21, pp.224, (Summary Text) Sustainable Development

64. Clinical outcomes in patients with locally advanced nasopharyngeal cancer treated with neoadjuvant docetaxel and cisplatin followed by radiation treatment and concomitant cisplatin

Ekenel M., Keskin S., Başaran M., Bavbek S., Özdemir C., Meral R., et al.

American Society of Clinical Oncology (ASCO®) 2010 Annual Meeting, Illinois, United States Of America, 4 - 08 June 2010, vol.28, pp.16017, (Summary Text) Sustainable Development

65. Evre I nonseminnmatöz testis kanserlerinde tedavisiz izlem sonuçlarımız

KESKİN S., EKENEL M., BAŞARAN M., BAVBEK S., ESEN T., ÖZCAN F., et al.

III. Tıbbi Onkoloji Kongresi, Antalya, Turkey, 24 - 28 March 2010, pp.6, (Full Text) Sustainable Development

66. Lokal ileri nazofarenks karsinomalı hastalarda neoadjuvan dosetaksel ve cisplatin sonrası kemoradyoterapi sonuçlarımız

EKENEL M., KESKİN S., BAŞARAN M., BAVBEK S., ÖZDEMİR C., MERAL R., et al.

III. Tıbbi Onkoloji Kongresi, Antalya, Turkey, 24 - 28 March 2010, pp.23, (Full Text)

67. Nefroblastom komponenti içeren testiküler teratom, literatürdeki ilk vaka

KESKİN S., EKENEL M., BAŞARAN M., BAVBEK S.

III. Tıbbi Onkoloji Kongresi, Antalya, Turkey, 24 - 28 March 2010, pp.126, (Full Text)

68. Opere lokal ileri mide kanserli hastalarda adjuvan kemoterapi ile kemoradyoterapinin etkinliğinin karşılaştırılması

ORDU C., KILIC L., EKENEL M., ŞAKAR B., AYKAN F.

III. Tıbbi Onkoloji Kongresi, Antalya, Turkey, 24 - 28 March 2010, pp.121, (Full Text) Sustainable Development

69. Nonseminomatöz germ hücreli testis tümörlerinde markır yarı ömrünün nüks eden ve etmeyen hasta gruplarında değerlendirilmesi

KESKİN S., EKENEL M., BAŞARAN M., BAVBEK S.

III. Tıbbi Onkoloji Kongresi, Antalya, Turkey, 24 - 28 March 2010, pp.7, (Full Text)

70. Paratestiküler rabdomyosarkomlu sekiz vakanın değerlendirilmesi

KESKİN S., EKENEL M., BAŞARAN M., BAVBEK S.

III. Tıbbi Onkoloji Kongresi, Antalya, Turkey, 24 - 28 March 2010, pp.123, (Full Text)

71. Does initial response to corticosteroids predict survival in primary CNS lymphoma (PCNSL)?

Ekenel M., IWAMOTO F. M., BEN PORAT L. S., DEANGELIS L. M., ABREY L. E.

14th European Cancer Conference (ECCO 14), Barcelona, Spain, 23 - 27 September 2007, vol.5, pp.228, (Summary Text)

72. Mide kanserinde VEGF, HIF-1 alfa, CD34, ekspresyonu ve bu faktörlerin prognostik önemi

CABUK D., BASARAN G., YUMUK F., CELIKEL C., DANE F., IYIKESICI M., et al.

I. Tıbbi Onkoloji Kongresi, Antalya, Turkey, 29 March - 02 April 2006, pp.17 Sustainable Development

73. Outcome of adjuvant treatment in turkish breast cancer (BC) patients (PTS): Single institution experience

CABUK D., BASARAN G., IYIKESICI S., Ekenel M., DANE F., TEOMETE M., et al.

31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.109, (Summary Text) Sustainable Development

74. Outcome of patients with stage III and IV non-small cell lung cancer in Marmara University Hospital, Istanbul, Turkey

IYIKESICI M., YUMUK P., DANE F., Ekenel M., BASARAN G., TURHAL N.

11th World Conference on Lung Cancer, Barcelona, Spain, 3 - 06 July 2005, vol.49, (Summary Text) Sustainable Development

75. The prognostic impact of body mass index (BMI) in early breast cancer (BC) patients (pts).

IYIKESICI M., KEFELI U., BASARAN G., DANE F., Ekenel M., YUMUK P., et al.

41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 13 - 17 May 2005, vol.23, (Summary Text) Sustainable Development

76. Clinical and pathological characteristics of early breast cancer (EBC) patients < 35 years old.

BASARAN G., DANE F., IYIKESICI S., Ekenel M., YUMUK F., TURHAL S.

41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 13 - 17 May 2005, vol.23, (Summary Text) Sustainable Development

77. VEGF, HIF-1 alpha and CD34 expressions in gastric tumors (tms): Relationship with pathological factors and prognostic impact on survival.

CABUK D., BASARAN G., YUMUK P., CELIKEL C., DANE F., IYIKESICI M., et al.

41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 13 - 17 May 2005, vol.23, (Summary Text)

78. Outcome of adjuvant treatment in elderly Turkish breast cancer patients.

Ekenel M., BASARAN G., DANE F., IYIKESICI S., YUMUK F., TURHAL S.

41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 13 - 17 May 2005, vol.23, (Summary Text) Sustainable Development

79. Meme kanseri hastalarında HPV-DNA amplifikasyonu ve p53 ekspresyonununprognostik değeri

YUMUK F., GUMUS M., DANE F., KAYA H., ALAM K., IYIKESICI M. S., et al.

X VI. Ulusal Kanser Kongresi, Antalya, Turkey, 20 - 24 April 2005, pp.12, (Full Text) Sustainable Development

80. Marmara üniversitesi hastanesindeki evre III ve IV küçük hücrei dışı akciğer kanserli hastaların sonuçları

IYIKESICI M. S., YUMUK F., DANE F., BASARAN G. A., EKENEL M., ABACIOGLU U., et al.

XVI. Ulusal Kanser Kongresi, Antalya, Turkey, 20 - 24 April 2005, pp.75, (Full Text) Sustainable Development

81. Knoxville Tennessee USA de evre III ve IV küçük hücreli akciğer kanserli hastaların sonuçları

TURHAL N. S., YUMUK F., IYIKESICI M. S., DANE F., BASARAN G., EKENEL M., et al.

X VI. Ulusal Kanser Kongresi, Antalya, Turkey, 20 - 24 April 2005, pp.77, (Full Text) Sustainable Development

82. Kemoterapi verilen lokal ileri veya metastatik küçük hücreli dışı akciğer kanseri hastalarının sağkalım ve prognostik açıdan değerlendirilmesi

YUMUK F., IYIKESICI M., GUMUS M., ALIUSTAOGLU M., DANE F., BASARAN G., et al.

1. Ulusal Torasik Onkoloji Kongresi, Antalya, Turkey, 7 - 10 October 2004, pp.37, (Full Text) Sustainable Development

83. Paclitaxel (P) (day 1 and 8) and carboplatin (C) given on every 3 weeks in advanced (stage III-IV) non-small cell lung cancer (NSCLC).

YUMUK P., TURHAL N., GUMUS M. D., HATABAY N., TURKEN O., OZKAN A., et al.

40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22 Sustainable Development

84. Prognostic value of thymidylate synthase and cox-2 expression in colorectal cancer patients' tumors.

ALIUSTAOGLU M., GUMUS M. D., MIDI A., CELIKEL C., Ekenel M., YUMUK F., et al.

40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22 Sustainable Development

85. Is the incidence of anal canal cancers different in Moslem societies?

CABUK D., YUMUK P., ABACIOGLU U., DEMIR G., DANE F., GUMUS M. D., et al.

40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22 Sustainable Development

86. Human papilloma virus: Is it a new etiological factor in breast cancer?

GUMUS M. D., YUMUK F., SALEPCI T., ALIUSTACGLU M., Ekenel M., BASARAN G., et al.

40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22, (Summary Text) Sustainable Development

87. FOLFOX4 in metastatic colorectal cancer (MCRC) patients who progressed after infusional 5-FU/irinotecan based combination regimens.

DANE F., YUMUK P., TURHAL N., Ekenel M., BASARAN G., IYIKESICI M., et al.

40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22 Sustainable Development

88. Adjuvan treatment outcome of high risk stage II and III colon cancer patients treated in Marmara University hospital

DANE F., IYIKESICI M., GUMUS M., YUMUK F., EKENEL M., BASARAN G., et al.

15th ICACT, Paris, France, 9 - 12 February 2004, vol.-, (Full Text) Sustainable Development

89. Mantle cell lymphoma presenting as abreast mass

GÜNDÜZ F., YUMUK F., DANE F., PEKER Ö., EKENEL M., IYIKESICI M., et al.

15th ICACT, Paris, France, 9 - 12 February 2004, vol.-, (Full Text)

90. Premenopozal meme kanseri hastalarında kemoterapiye bağlı amenore insidansı ve prognostik rolü

EKENEL M., BASARAN G., GUMUS M., ALIUSTAOGLU M., DANE F., YUMUK F., et al.

VII. Ulusal Meme Hatalıkları Kongresi, Antalya, Turkey, 16 - 19 October 2003, pp.170, (Full Text) Sustainable Development

91. Meme kanserli hastalarda normal ve tümöral doku örnrklerinde human papillomavirüs (HPV)DNA sıklığı ve HPV tip tayini

GUMUS M., DANE F., ALIUSTAOGLU M., YUMUK F., EKENEL M., SALEPCI T., et al.

VII. Ulusal Meme Hatalıkları Kongresi, Antalya, Turkey, 16 - 19 October 2003, pp.144, (Full Text) Sustainable Development

92. The survival characteristics of the stage IIIB and IV non-small cell lung cancer patients in Marmara University hospital in İstanbul, Turkey.

ALIUSTAOGLU M., GUMUS M., YUMUK F., EKENEL M., KARAMANOGLU A., SENGOZ M., et al.

IASLC, Vancouver, Canada, 10 - 14 August 2003, vol.-, (Full Text) Sustainable Development

93. Prognostic factors and treatment outcomes of adjuvant breast cancer patients in two locations; Tennesee, USA and İstanbul, turkey

TURHAL N. S., GUMUS M., EKENEL M., GÜZET E., YUMUK F., AVERY B.

ASCO, Chicago, United States Of America, 31 May - 03 June 2003, vol.-, (Summary Text) Sustainable Development

94. Evre III over kanserinde kemoterapi sonuçlarımız

ALIUSTAOGLU M., TURHAL N. S., EKENEL M., GUMUS M., YUMUK F.

XV. Ulusal Kanser Kongresi, Antalya, Turkey, 23 - 27 April 2003, vol.-, pp.112, (Full Text) Sustainable Development

95. The absence of irinotecan associated acute diarrhea with atropine premedication

AYDIN S., YUMUK F., EKENEL M., GUMUS M., ALIUSTAOGLU M., KARAMANOGLU A., et al.

14th ICACT, Paris, France, 1 - 04 February 2003, vol.-, (Full Text) Sustainable Development

96. Incidence of chemotherapy induced amenorrhea in premenopausal Turkish breast cancer patients

EKENEL M., BASARAN G., GUMUS M., YUMUK F., ALIUSTAOGLU M., KARAMANOGLU A., et al.

14th ICACT, Paris, France, 1 - 04 February 2003, vol.-, (Full Text) Sustainable Development

97. Outcome of breast cancer patients after adjuvant therapy in İstanbul, Turkey

EKENEL M., BASARAN G. A., GUMUS M., YUMUK F., ALİUSTAOĞLU M., KARAMANOGLU A., et al.

14th ICACT, Paris, France, 1 - 04 February 2003, vol.-, (Full Text) Sustainable Development

98. Attitude towards genetic testing in Turkish society

GUMUS M., BASARAN G. A., ALIUSTAOGLU M., GÜLER S., EKENEL M., KARAMANOGLU A., et al.

11th European Cancer Conference, Lizbon, Portugal, 21 - 25 October 2001, vol.-, (Full Text)

99. Plasma D-dimer levels in patients with benign and malignant gastric lesions

ALİUSTAOĞLU M., YUMUK F., GUMUS M., EKENEL M., BOLUKBAS F., BOLUKBAS C., et al.

European Society of Medical Oncology, Hamburg, Germany, 13 - 17 October 2000, vol.-

Books 3

Metrics

Publication

173

Publication (WoS)

Publication (Scopus)

Citation (WoS)

2187

H-Index (WoS)

Citation (Scopus)

2384

H-Index (Scopus)

Citation (Scholar)

H-Index (Scholar)

Project

Thesis Advisory

Open Access

UN Sustainable Development Goals

Publications & Works